EricTopol Eric Topol
3 years 4 months ago
An inhaled Covid vaccine booster was more than 5-fold effective for inducing neutralizing antibodies at 28-days, and more durable at 1-year, than shots, vs Omicron BA.5 in a randomized trial
https://t.co/yeHxgukgft @TheLancetInfDis https://t.co/drpQuw0yiN
Editor's Note: please note the error in the original report has been corrected to read: UCB affirms there are no open information requests from the FDA regarding the BLA for bimekizumab or bimekizumab manufacturing.
Dr. John Cush RheumNow
3 years 4 months ago
EULAR 2023 Lupus Highlights
https://t.co/xsqKvYmBWi https://t.co/mNRc1xUvam
Dr. John Cush RheumNow
3 years 4 months ago
TitAIN Study: Secukinumab Efficacy in Giant Cell Arteritis
A phase 2 trial has demonstrated the efficacy of secukinumab, an anti-interleukin-17A monoclonal antibody, in patients with active giant cell arteritis (GCA).
https://t.co/rDZSQa6wCt https://t.co/WoqK8cpfxC
Dr. John Cush RheumNow
3 years 4 months ago
Belimumab in adult inflamm myositis (IIM)? Small study 15 IIM pts recv ≥ 5 doses of belimumab or placebo; Treatment success (TIS ≥ 40) was more common with BEL (55% vs 33%) as was defined improvement (DOI: 33% vs 17%); not signif, but interesting! https://t.co/CG9ClLHEW6 https://t.co/DPekHWjTsP
Dr. John Cush RheumNow
3 years 4 months ago
The Importance of Knowing Which Entheses are Involved in PsA
Dr. Eric Ruderman discusses abstract POS0027 presented at EULAR 2023 in Milan, Italy.
https://t.co/3RqnkGB9vn https://t.co/AaJd04MLx0
Dr. John Cush RheumNow
3 years 4 months ago
Arborviral infx w/ rituximab? 21 RTX pts dx w/ arboviral neuroinvasive Dz, (encephalitis, acute flaccid myelitis); 79% died. B cell depletion impairs immunity & spread of West Nile Virus, serologic Ab Dx tests; thus if suspected, order RT-PCR tests https://t.co/I6A8F4Kx7a https://t.co/njyciZFn52
Dr. John Cush RheumNow
3 years 4 months ago
NY Times article on a Moral Crisis for Americas doctors - the corporatization of Medicine leverages finances/incomes against physican values and practice preferences. Rheum Dr. Diana Girnita presents the Direct Medical Care option for MD autonomy https://t.co/gd0YAX4cOb https://t.co/DWwCFVtBfL
Recurrent bouts of systemic lupus erythematosus, marked by the body’s immune system attack of its own tissues, closely tracked with measurable upticks in growth in the gut of a certain species of bacteria.
A multicenter cohort study reported a large cohort of pediatric patients receiving TNF inhibitor therapy complicated by psoriasis, regardless of treatment indication or the specific TNF inhibitor.
Paradoxical psoriasis arising from TNF inhibition has been well described in adults, with a reported risk between 1/100 and 1/1000.
Obesity carries many risks, now a new study in Arthritis & Rheumatology shows that higher body mass index (BMI) increases the risk for several rheumatic diseases, especially in women for both gout and psoriatic arthropathy.
Dr. John Cush RheumNow
3 years 4 months ago
FDA has approved a 2nd JAK inhibitor for Alopecia areata - Pfizers Ritlecitinib (Litfulo) is approved for Adults and Adolescents (>12 yrs) With Severe Alopecia Areata (based on ALLEGRO trial, pub in Lancet) https://t.co/VmjhQOnZyS https://t.co/VmjhQOnZyS https://t.co/oUZfckt6DX
Dr. John Cush RheumNow
3 years 4 months ago
Why Patients Don't Take Medicines
This report examines the characteristics of adults aged 18–64 who took prescription medication in the past 12 months and did not take medication as prescribed due to cost.
https://t.co/zuPgMjKYbh https://t.co/62cG9LDYWi
Dr. John Cush RheumNow
3 years 4 months ago
c-Fos regulates chondrocyte proliferation and differentiation, and cFOS-positive chondrocytes were increased in human and murine OA cartilage. New research (humans an mice) suggests it plays a role in protecting cartilage and could be a therpeutic target https://t.co/B0tmo0AbQe https://t.co/KPrOm3Spfa
Dr. John Cush RheumNow
3 years 4 months ago
FDA Approves Colchicine for CV Prevention
The FDA has approved colchicine for cardiovascular prevention in adults with established atherosclerotic disease or multiple risk factors, making it the first anti-inflammatory medicine with such an indication.
https://t.co/MEqASrWWMb https://t.co/TmoLEvlPXI
